Combined Phase 3 Double-blind Randomized Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Crohn's Disease
  • Age: Between 18 - 75 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on the date of the screening visit
    2. Documented diagnosis of CD with a minimum disease duration of 6 months Moderately to severely active CD

You may not be eligible for this study if the following are true:

    1. Current complications of CD such as symptomatic strictures, severe rectal/anal stenosis, fistulae, short bowel syndrome, etc.
    2. Use of any prohibited concomitant medications as described in the study protocol that will be reviewed by study staff
    3. Participants may be eligible for long term extension treatment (up to 144 weeks)after completion of above protocol

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.